drugset / Trial / NCT02126358

Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

NCT02126358

Phase 3 Completed 290 enrolled LG Life Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia

Timeline

Start
2014-05
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg
Subject Rosuvastatin Small molecule 20 mg